Equities Analysts Set Expectations for Thermo Fisher Scientific Inc.’s Q2 2021 Earnings (NYSE:TMO)


Share on StockTwits

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at KeyCorp increased their Q2 2021 EPS estimates for shares of Thermo Fisher Scientific in a report issued on Thursday, April 29th. KeyCorp analyst P. Knight now forecasts that the medical research company will post earnings of $5.32 per share for the quarter, up from their prior forecast of $5.20. KeyCorp has a “Overweight” rating and a $520.00 price objective on the stock. KeyCorp also issued estimates for Thermo Fisher Scientific’s Q3 2021 earnings at $4.63 EPS and FY2021 earnings at $22.00 EPS.

TMO has been the topic of several other research reports. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $525.00 to $540.00 and gave the company an “outperform” rating in a report on Thursday, April 22nd. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $535.00 to $575.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 2nd. BTIG Research raised their price objective on Thermo Fisher Scientific from $540.00 to $590.00 and gave the company a “buy” rating in a research report on Wednesday, February 3rd. UBS Group decreased their target price on Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating for the company in a research report on Monday, March 29th. Finally, SVB Leerink boosted their price target on Thermo Fisher Scientific from $525.00 to $560.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 2nd. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average price target of $534.45.

NYSE TMO opened at $465.28 on Monday. The business’s 50-day simple moving average is $468.42 and its 200-day simple moving average is $476.02. The firm has a market capitalization of $182.86 billion, a P/E ratio of 38.14, a P/E/G ratio of 1.40 and a beta of 0.85. Thermo Fisher Scientific has a 1-year low of $324.35 and a 1-year high of $532.57. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.93 and a quick ratio of 2.31.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, April 29th. The medical research company reported $7.21 earnings per share for the quarter, topping the consensus estimate of $6.69 by $0.52. The business had revenue of $9.91 billion for the quarter, compared to analyst estimates of $9.69 billion. Thermo Fisher Scientific had a return on equity of 21.35% and a net margin of 17.12%. The business’s quarterly revenue was up 59.0% on a year-over-year basis. During the same period last year, the company posted $2.94 EPS.

The company also recently declared a quarterly dividend, which was paid on Friday, April 16th. Investors of record on Tuesday, March 16th were paid a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.22%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend was Monday, March 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 8.42%.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC lifted its stake in Thermo Fisher Scientific by 38.5% during the fourth quarter. Larson Financial Group LLC now owns 72 shares of the medical research company’s stock worth $34,000 after purchasing an additional 20 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 6,921 shares of the medical research company’s stock valued at $3,224,000 after buying an additional 20 shares during the period. S.A. Mason LLC grew its position in shares of Thermo Fisher Scientific by 8.7% during the 4th quarter. S.A. Mason LLC now owns 250 shares of the medical research company’s stock valued at $116,000 after buying an additional 20 shares during the last quarter. Crescent Capital Consulting LLC lifted its holdings in Thermo Fisher Scientific by 2.8% in the first quarter. Crescent Capital Consulting LLC now owns 781 shares of the medical research company’s stock worth $357,000 after acquiring an additional 21 shares during the last quarter. Finally, CFO4Life Group LLC grew its holdings in shares of Thermo Fisher Scientific by 1.8% during the fourth quarter. CFO4Life Group LLC now owns 1,216 shares of the medical research company’s stock valued at $567,000 after purchasing an additional 22 shares during the last quarter. Hedge funds and other institutional investors own 87.17% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also: Special Purpose Acquisition Company (SPAC) – What You Need to Know

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.